A carregar...
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab (FCR) begs the question of the value of minimal residual disease (MRD)–negative status as a treatment end point. We report on 237 patients with chronic lymphocytic leukemia who received first-line...
Na minha lista:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4067501/ https://ncbi.nlm.nih.gov/pubmed/24705492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-538116 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|